Skip to main content

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies

We are redefining therapeutics by leveraging new protein building blocks to transform treatment for countless patients.

More About Us

Watch the Company Overview

The GRO Platform

The GRO platform expands the amino acid alphabet to overcome the limitations of protein therapeutics currently impeding the treatment of disease

We’re delivering on the long-awaited promise of protein therapeutics by solving the intrinsic limitations of proteins on potency, stability, and function. The GRO platform shortens development timelines and is the only system capable of seamlessly scaling production of NSAA (non-standard amino acid) proteins to meet clinical needs.

LEARN MORE
Solid GRO Bioscience Blue Circle
Gradient Circle
Science Woman
Gradient Circle Overlay

Our Pipeline

Today, we’re focused on our first two families of NSAA chemistries to drive our product pipeline

GRObio is advancing its first two families of NSAA chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side-effects of protein-based therapies.

LEARN MORE
Light Blue Solid Circle
Gradient Background Circle
Elderly Man with grandson
Gradient Circle Overlay

Featured News

December 21, 2022 in Featured News, News

The 2023 PharmaVoice Year in Preview

Every year brings its own distinct changes. For the life sciences industry, 2022 was marked by challenges such as the ongoing influence of the pandemic, a turbulent economy and a…
Read More
December 7, 2022 in Featured News, News

Finding Genius: Engineering Proteins To Enhance Medicine With GRO Biosciences CEO Daniel J. Mandell

In this episode, we sit down with scientist and entrepreneur Daniel J. Mandell, Ph.D. Daniel is the Chief Executive Officer, Co-Founder, and Director of GRO Biosciences, a genome engineering, computational…
Read More
September 28, 2022 in Featured News, News

Drug Target Review: Synthetic biology is ready for the therapeutic limelight

After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell,…
Read More
VIEW ALL NEWS